Treats hypertension. ANDA 204382, held by Amneal Pharms. Hydrochlorothiazide; Valsartan.
As of Nov 16, 2026, ANDA 204382 (Valsartan And Hydrochlorothiazide), held by Amneal Pharms, was first approved by FDA on Aug 11, 2023, with 0 approved supplements and 0 published complete response letters.
Valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2023 | Original application | Approved | None posted |
| Valsartan And Hydrochlorothiazide12.5MG;80MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide12.5MG;160MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide25MG;160MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide12.5MG;320MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide25MG;320MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters